Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSHTDF -6.74%78 Forward Rate of Return (Yacktman) % is 17.96% as of Dec. 2025, which is 31% below its 10-year median of 26.02. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $2.58 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 84 Medical Distribution companies, Sinopharm Group Co ranks better than 82.14% on this metric.
Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Sinopharm Group Co's forward rate of return for was 17.96%.
The historical rank and industry rank for Sinopharm Group Co's Forward Rate of Return (Yacktman) % or its related term are showing as below:
SHTDF'
s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 18.13 Med: 26.02 Max: 36.57
Current: 20.66
During the past 13 years, Sinopharm Group Co's highest Forward Rate of Return was 36.57. The lowest was 18.13. And the median was 26.02.
SHTDF's Forward Rate of Return (Yacktman) % is ranked better than 82.14% of 84
companies
in the Medical Distribution industry
Industry Median: 9.125
vs SHTDF: 20.66
Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Sinopharm Group Co (OTCPK:SHTDF) Forward Rate of Return (Yacktman) % Explanation
Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.
Be Aware
In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.
Sinopharm Group Co Forward Rate of Return (Yacktman) % Related Terms
Sinopharm Group Co Forward Rate of Return (Yacktman) % Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Forward Rate of Return (Yacktman) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co Forward Rate of Return (Yacktman) % Chart
SHTDF vs MCK, CAH, COR: Forward Rate of Return (Yacktman) % Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Forward Rate of Return (Yacktman) % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Forward Rate of Return (Yacktman) % distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Forward Rate of Return (Yacktman) % falls into.
Sinopharm Group Co Forward Rate of Return (Yacktman) % Calculation
Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):
If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.
The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Rate of Return (Yacktman) % of 17.96% mean?
Sinopharm Group Co (SHTDF) has a Forward Rate of Return (Yacktman) % of 17.96% as of Dec. 2025. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Sinopharm Group Co and its competitors. This is 31% below median its historical median of 26.02. Over the past decade, Sinopharm Group Co's Forward Rate of Return (Yacktman) % has ranged from 18.13 to 36.57. According to the industry distribution chart, Sinopharm Group Co ranks #15 out of 84 companies in the Medical Distribution industry, placing it in the top 17.9%.
Is Sinopharm Group Co's Forward Rate of Return (Yacktman) % too high?
Sinopharm Group Co's current Forward Rate of Return (Yacktman) % of 17.96% is 31% below median its 10-year median of 26.02. Over the past 10 years, this metric has ranged from a low of 18.13 to a high of 36.57. The Medical Distribution industry median Forward Rate of Return (Yacktman) % is 9.13. Sinopharm Group Co's value of 17.96% is 96.8% above this industry median. Based on the distribution chart, Sinopharm Group Co ranks #15 out of 84 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Forward Rate of Return (Yacktman) % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #15 out of 84 companies for Forward Rate of Return (Yacktman) %. This places Sinopharm Group Co in the top 18% of its industry — outperforming the majority of peers. The industry median Forward Rate of Return (Yacktman) % is 9.13. Sinopharm Group Co's value of 17.96% is 96.8% above this benchmark. Historically, Sinopharm Group Co's own Forward Rate of Return (Yacktman) % has ranged from 18.13 to 36.57 over the past decade. While the company's 10-year median is 26.02 vs. the industry median of 9.13, Sinopharm Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Rate of Return (Yacktman) % for a Medical Distribution company?
The median Forward Rate of Return (Yacktman) % among Medical Distribution companies is 9.13, based on 84 companies in the industry. Companies in the top quartile (top 25%) have a Forward Rate of Return (Yacktman) % significantly above this median, while those in the bottom quartile fall well below. However, Forward Rate of Return (Yacktman) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Forward Rate of Return (Yacktman) % of 17.96% is 96.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Rate of Return (Yacktman) % mean?
A high Forward Rate of Return (Yacktman) % can signal that a stock is expensive relative to its fundamentals. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Forward Rate of Return (Yacktman) % is 9.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Forward Rate of Return (Yacktman) % is 17.96%, which is 31% below median its own 10-year median of 26.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.58, compared to a current price of $2.13 — trading 17.3% below its estimated fair value. The current Forward Rate of Return (Yacktman) % is 17.96%, which is 31% below median its 10-year median of 26.02 and 96.8% above the Medical Distribution industry median of 9.13. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Rate of Return (Yacktman) % calculated?
Forward Rate of Return (Yacktman) % is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Forward Rate of Return (Yacktman) % is 17.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.13 is trading 17.3% below its estimated GF Value™ of $2.58.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
Forward Rate of Return (Yacktman) %: 17.96% (31% below median its 10-year median of 26.02)
GF Value™: $2.58 vs. price of $2.13 (17.3% below fair value)
Industry Position: 96.8% above the Medical Distribution median (#15 of 84)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
Forward Rate of Return (Yacktman) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
